{"entity":{"id":"nct07085767","kind":"trial","name":"Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer","aka":[],"tldr":"A phase 3 trial of Ribociclib in HR-positive / HER2-negative breast cancer, run by Olema Pharmaceuticals, Inc., now recruiting.","summary":"Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer is a phase 3 interventional study registered as NCT07085767 by Olema Pharmaceuticals, Inc., with 1000 participants planned, started 2025-11-03 and due to reach its primary completion in 2028-12. Interventions recorded: Palazestrant, Letrozole-matching placebo, Ribociclib, Letrozole and Palazestrant matching-placebo.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07085767","url":"https://clinicaltrials.gov/study/NCT07085767"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["ribociclib"],"companies":["olema-pharmaceuticals","advanced-accelerator-applications"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07085767","phase":"3","setting":"A Phase 3 Randomized, Double-Blind, Active-Controlled Study of Palazestrant With Ribociclib Versus Letrozole With Ribociclib for the First-Line Treatment of ER+, HER2- Advanced Breast Cancer (OPERA-02)","sponsor":"Olema Pharmaceuticals, Inc.","enrolled":1000,"outcomes":[]},"route":"/trials/nct07085767/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"drug":[{"id":"ribociclib","kind":"drug","name":"Ribociclib","route":"/drugs/ribociclib/"}],"company":[{"id":"advanced-accelerator-applications","kind":"company","name":"Advanced Accelerator Applications (Novartis)","route":"/companies/advanced-accelerator-applications/"},{"id":"olema-pharmaceuticals","kind":"company","name":"Olema Pharmaceuticals","route":"/companies/olema-pharmaceuticals/"}]}}